The oncogenic MUC1 C-terminal subunit (MUC1-C) subunit is aberrantly overexpressed in most human breast
cancers by mechanisms that are not well understood. The present studies demonstrate that stimulation of non-malignant MCF-10A cells with
epidermal growth factor (
EGF) or
heregulin (
HRG) results in marked upregulation of MUC1-C translation.
Growth factor-induced MUC1-C translation was found to be mediated by PI3KAKT, and not by MEKERK1/2, signaling. We also show that activation of the
mammalian target of rapamycin complex 1 (
mTORC1)ribosomal
protein S6 kinase 1 (S6K1) pathway decreases
tumor suppressor
programmed cell death protein 4 (PDCD4), an inhibitor of the eIF4A
RNA helicase, and contributes to the induction of MUC1-C translation. In concert with these results, treatment of
growth factor-stimulated MCF-10A cells with the eIF4A
RNA helicase inhibitors,
silvestrol and CR-1-31-B, blocked increases in MUC1-C abundance. The functional significance of the increase in MUC1-C translation is supported by the demonstration that MUC1-C, in turn, forms complexes with
EGF receptor (EGFR) and promotes EGFR-mediated activation of the PI3KAKT pathway and the induction of growth. Compared with MCF-10A cells, constitutive overexpression of MUC1-C in
breast cancer cells was unaffected by
EGF stimulation, but was blocked by inhibiting PI3KAKT signaling. The overexpression of MUC1-C in
breast cancer cells was also inhibited by blocking eIF4A
RNA helicase activity with
silvestrol and CR-1-31-B. These findings indicate that
EGF-induced MUC1-C expression is mediated by the PI3KAKT pathway and the eIF4A
RNA helicase, and that this response promotes EGFR signaling in an autoinductive loop. The findings also indicate that targeting the eIF4A
RNA helicase is a novel approach for blocking MUC1-C overexpression in
breast cancer cells.